Protagenic Therapeutics (OTCMKTS:PTIX) and PFSweb (NASDAQ:PFSW) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.
Insider and Institutional Ownership
57.7% of PFSweb shares are held by institutional investors. 51.1% of Protagenic Therapeutics shares are held by company insiders. Comparatively, 6.5% of PFSweb shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Protagenic Therapeutics and PFSweb, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Protagenic Therapeutics | 0 | 0 | 0 | 0 | N/A |
PFSweb | 0 | 1 | 3 | 0 | 2.75 |
PFSweb has a consensus price target of $10.33, suggesting a potential upside of 172.65%. Given PFSweb’s higher possible upside, analysts clearly believe PFSweb is more favorable than Protagenic Therapeutics.
Profitability
This table compares Protagenic Therapeutics and PFSweb’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Protagenic Therapeutics | N/A | -3,446.47% | -315.73% |
PFSweb | 0.25% | 12.07% | 3.14% |
Volatility & Risk
Protagenic Therapeutics has a beta of -7.89, suggesting that its share price is 889% less volatile than the S&P 500. Comparatively, PFSweb has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.
Earnings & Valuation
This table compares Protagenic Therapeutics and PFSweb’s top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Protagenic Therapeutics | N/A | N/A | -$2.56 million | N/A | N/A |
PFSweb | $326.16 million | 0.23 | $1.23 million | $0.29 | 13.07 |
PFSweb has higher revenue and earnings than Protagenic Therapeutics.
Summary
PFSweb beats Protagenic Therapeutics on 9 of the 10 factors compared between the two stocks.
About Protagenic Therapeutics
About PFSweb
Receive News & Ratings for Protagenic Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Protagenic Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.